



Patent Docket P1942R1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Anan Chunthrapai et al. Serial No.: 10/626,914 Filed: July 25th, 2003 For: TACI Antibodies and Uses Thereof	Group Art Unit: Not Yet Assigned Examiner: Not Yet Assigned Confirmation No: Not Yet Assigned CUSTOMER NO: 09157
<p style="text-align: center;">CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on</p> <p style="text-align: center;">February 20 2004 <i>T.E. Marrs</i> Tom Marrs</p>	

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants submit herewith patents, publications or other information (attached hereto and listed on the attached Form PTO-1449) of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement is filed in accordance with the provisions of:

37 CFR §1.97(b)

- within three months of the filing date of the application other than a continued prosecution application under 37 CFR §1.53(d); **or**
- within three months of the date of entry of the national stage of a PCT application as set forth in 37 CFR§1.491, **or**
- before the mailing of the first Office action on the merits; **or**
- before the mailing of the first Office action after the filing of a request for a continued examination under 37 CFR §1.114.

37 CFR §1.97(c)

- by the applicant after the period specified in 37 CFR §1.97(b), but prior to the mailing date of any of a final action under 37 CFR §1.113, or a notice of

allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application, and is accompanied by either the fee set forth in 37 CFR §1.17(p) **or** a statement as specified in 37 CFR §1.97(e), as checked below.

37 CFR §1.97(d)

- after the period specified in CFR §1.97(c), and is accompanied by the fee set forth in 37 CFR §1.17(p) **and** a statement as specified in 37 CFR §1.97(e), as checked below.

(If either of boxes 37 CFR §1.97(c) or 37 CFR §1.97(d) is checked above, the following statement under 37 CFR §1.97(e) may need to be completed.)

- 0 **37 CFR §1.97(e)** Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- 0 **37 CFR §1.704(d)** Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and the communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of this information disclosure statement. Therefore, in accordance with the provisions of 37 CFR §1.704(d), the filing of this information disclosure statement will not be considered a failure to engage in reasonable efforts to conclude prosecution under 37 CFR §1.704.
- 0 The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p). Any deficiency or overpayment should be charged or credited to this deposit account.

A list of the patent(s) or publication(s) is set forth on the attached Form PTO-1449. Copies of all items listed on Form PTO-1449 are supplied herewith, except for the United States patents. Pursuant a Patent Office waiver signed July 11, 2003, applicants are no longer required to submit copies of United States patents cited in information disclosure statements in applications filed after June 30, 2003 (1276 OG 55). Nevertheless, applicants stand ready to provide copies at the request of the Examiner.

A concise explanation of relevance of the items listed on PTO-1449 is:

not given

given for each listed item

- given for only non-English language listed item(s) (Required)
- in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.


In accordance with 37 CFR §1.97(g), the filing of this information disclosure statement shall not be construed as a representation that a search has been made.

In accordance with 37 CFR §1.97(h), the filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17 for this Information Disclosure Statement, or credit overpayment to Deposit Account No. 07-0630.

Respectfully submitted,

GENENTECH, INC.

By: 
Elinor K. Shin
Reg. No. 43,117
Telephone No. (650)225-3536

Date: February 26, 2004

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1942R1	Serial No. 10/626,914
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Chuntharapai et al.	
				Filing Date 25 Jul 2003	Group Not Yet Assigned

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
/RBS/	1	5,969,102	19.10.99	Bram et al.			
/RBS/	2	6,316,222 B1	13.11.01	Bram et al.			
/RBS/	3	6,500,428	31.12.02	Bram et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes No
/RBS/	4	WO 00/40716	13.07.00	PCT			
	5	WO 00/67034	09.11.00	PCT			
	6	WO 01/81417	01.11.01	PCT			
	7	WO 01/85782	15.11.01	PCT			
	8	WO 01/87977	22.11.01	PCT			
	9	WO 01/87979	22.11.01	PCT			
	10	WO 02/066516	29.08.02	PCT			
	11	WO 02/46231	13.06.02	PCT			
	12	WO 98/39361	11.09.98	PCT			

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

	13	Gross et al., "TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease" <u>Nature</u> 404:995-999 (2000)
	14	Mammalian Gene Collection (MGC) Program Team, "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences" <u>Proc. Natl. Acad. Sci. USA</u> 99(26):16899-16903 (2002)
	15	RIKEN Genome & FANTOM Consortium, "Functional annotation of a full-length mouse cDNA collection" <u>Nature</u> 409(6821):685-690 (2001)
	16	Seshasayee et al., "Loss of TACI Causes Fatal Lymphoproliferation and Autoimmunity, Establishing TACI as an Inhibitory BLyS Receptor" <u>Immunity</u> 18:279-288 (2003)
	17	von Bulow and Bram, "NF-AT Activation Induced by a CAML-Interacting Member of the Tumor Necrosis Factor Receptor Superfamily" <u>Science</u> 278:138-141 (1997)
	18	von Bulow et al., "Regulation of the T-independent Humoral Response by TACI" <u>Immunity</u> 14:573-582 (2001)
	19	Xia et al., "TACI Is a TRAF-interacting Receptor for TALL-1, a Tumor Necrosis Factor Family Member Involved in a B Cell Regulation" <u>Journal of Experimental Medicine</u> 192:137-143 (2000)
	20	Xu et al., "B-Cell Maturation Protein, Which Binds the Tumor Necrosis Factor Family Members BAFF and APRIL, Is Dispensable for Humoral Immune Responses" <u>Mol. Cell. Biology</u> 21:4067-4074 (2001)
	21	Yan et al., "Activation and accumulation of B cells in TACI-deficient mice" <u>Nature Immunology</u> 2:638-643 (2001)
↓	22	Yan et al., "Identification of a receptor for BLyS demonstrates a crucial role in humoral immunity" <u>Nature Immunology</u> 1:37-41 (2000)

Examiner	/Ron Schwadron/	Date Considered	4/22/08
----------	-----------------	-----------------	---------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.